Navigation Links
Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/30/2008

-- Third Sequential Profitable Quarter --

-- Conference Call on Monday, March 31, 2008 at 9:00 a.m. ET --

BEIJING, March 31 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced unaudited financial results for the three months and twelve months ended December 31, 2007.

Highlights

-- Record full year 2007 sales of $33.5 million, up 118% year-over-year

-- Record full year 2007 net income of $7.7 million, or $0.19 per share

-- Fourth quarter 2007 sales increased 49% year-over-year to $9.2 million

-- Fourth quarter 2007 operating income rose 460% year-over-year to

$3.3 million

-- Fourth quarter 2007 net income increased to $2.0 million, or $0.05

per share

-- Reported positive preliminary Phase II results for pandemic influenza

(H5N1) whole viron vaccine

-- Sold 5.12 million doses of Healive(R) in 2007, up from 2.6 million

in 2006

-- Sold 1.59 million doses of Anflu(R) in 2007, up from 77,000 doses in

in 2006

Mr. Weidong Yin, Chairman, President and CEO, stated, ''2007 was a record year for Sinovac from a commercialization and a clinical development standpoint. Exceeding our internal projections for year-over-year sales growth, our 2007 sales increased 118%, due to higher than anticipated sales of our lead products, Healive(R), our inactivated hepatitis A vaccine, and Anflu(R), our seasonal influenza vaccine, based on the proactive efforts of our sales organization across China. In addition, we entered a promotion agreement with GSK China for our seasonal influenza vaccine, Anflu(R), and successfully launched a marketing campaign that yielded sales in the second half of the year. We advanced the clinical development of our pandemic influenza vaccine formulations. We successfully completed the Phase II trial of our whole viron vaccine in 2007 that led to the submission with the SFDA during the first quarter of 2008. Most recently during the first quarter of 2008, the Phase I trial for the split inactivated vaccine was completed.''

Mr. Weidong Yin, Chairman, President and CEO, continued, ''The fourth quarter results marked our third sequential profitable quarter. Our quarterly sales reflected the continued demand for our lead product, Healive(R), our inactivated hepatitis A vaccine. Healive(R) was recently selected by the Beijing Centers for Disease Control and Prevention for the hepatitis A vaccination program.''

Full Year 2007

For twelve months ended December 2007, sales increased 118% to $33.5 million, compared to $15.4 million for 2006. The growth was attributable to strong sales of the Company's inactivated hepatitis A vaccine, Healive(R), and ongoing marketing initiatives in support of the Company's seasonal influenza vaccine, Anflu(R).

Gross profit for 2007 was $27.0 million, with a gross margin of 80.6%, compared to $11.1 million and 72.4%, respectively, for 2006. The higher gross margin resulted from the increased economies of scale and lower average unit costs associated with Healive(R) production and reflected normalized Anflu(R) production expenses.

Total operating expenses for the full year 2007 increased to $13.6 million, compared to $10.7 million in the same period of 2006. Selling, general and administrative (''SG&A'') expenses for 2007 were $12.0 million, compared to $9.8 million for 2006. The year-over-year increase in SG&A expenses reflected increased selling expense that is in line with the increase in sales, offset by decreased bad debt provision due to improvement in accounts receivable collection, decreased lower stock-based compensation and reduced consulting fees.

Aggregated research and development expenses for the full year 2007 were $1.8 million, compared to $1.2 million for 2006. The Company's net R&D expenses were $965,000 for 2007, compared to $325,000 for 2006. The R&D expenses recognized as a reduction to government grants were $844,000 for 2007, compared to $845,000 for 2006.

Operating income was $13.5 million for the full year 2007, compared to $440,000 for 2006. The year-over-year increase in operating income reflected the significant increase in vaccine sales.

Net income for the twelve months ended December 31, 2007 was $7.7 million, or $0.19 per diluted share, compared to a net loss of $696,000, or $0.02 per diluted share, for 2006. Net income for 2007 included $478,000 of interest and financing expenses, $2.0 million of income taxes, and $3.6 million of minority interest. Net income for 2006 included $319,000 of interest and financing expenses, $101,000 of income taxes, and $1.0 million of minority interest.

As of December 31, 2007, Sinovac's cash and cash equivalents totaled $17.1 million, compared to $9.2 million as of December 31, 2006.

Fourth Quarter 2007

For the fourth quarter 2007, sales increased 49% to $9.2 million, compared to $6.2 million in the fourth quarter 2006. The growth was attributable to strong sales of the Company's inactivated hepatitis A vaccine, Healive(R), and ongoing marketing initiatives in support of the Company's seasonal influenza vaccine, Anflu(R).

Gross profit for fourth quarter of 2007 was $6.3 million, with a gross margin of 68.3%, compared to $4.9 million and 78.9%, respectively, for the same period of 2006. The lower gross margin resulted primarily from lower margin sales of Anflu(R).

Total operating expenses for the fourth quarter of 2007 decreased to $3.0 million, compared to $4.3 million in the same period of 2006. Selling, general and administrative expenses for fourth quarter of 2007 were $2.5 million, compared to $4.0 million in the same period of 2006. The year-over-year decrease in SG&A expenses was attributable primarily to the partial reversal of bad debt provision in the fourth quarter of 2007 based on the improvement of account receivables and lower consulting fees.

Aggregated research and development expenses for the fourth quarter of 2007 were $756,000, compared to $300,000 in the same period of 2006. The Company's net R&D expenses were $354,000 for the fourth quarter of 2007, compared to $162,000 in the same period of 2006. The R&D expenses recognized as a reduction to government grants were $755,726 in the fourth quarter of 2007, compared to $299,776 in the same period of 2006.

Operating income was $3.3 million for the fourth quarter of 2007, compared to $588,000 in the same period of 2006. The year-over-year increase in operating income reflected the significant increase in vaccine sales and the lower operating expenses.

Net income for the fourth quarter of 2007 was $2.0 million, or $0.05 per diluted share, compared to $181,000, or $0.005 per diluted share, in the same period of 2006. Net income for the fourth quarter of 2007 included $294,000 of interest and financing expenses, $42,000 of income taxes, and $965,000 of minority interest. Net income for the same period of 2006 included $95,000 of interest and financing expenses, $405,882 of income taxes, and $559,000 of minority interest.

Sales and Marketing

During the twelve months ended December 31, 2007, Sinovac sold total 5.12 million doses of Healive(R), up from 2.6 million doses in 2006. During the fourth quarter of 2007, Sinovac sold approximately 1.14 million doses of Healive(R), up from 1.07 million for the same period of 2006. During the fourth quarter, the higher sales reflected Sinovac's ongoing marketing activities. The initiation of the government paid market for the hepatitis A vaccine in China is expected to impact the seasonality of Healive(R) sales established in previous years.

For the twelve months ended December 31, 2007, Sinovac sold 1.59 million doses of Anflu(R), which accounted for 14.3% of full year sales. During the fourth quarter of 2007, Sinovac sold 0.52 million doses of Anflu(R), which accounted for 27% of quarterly sales. Sinovac is co-marketing Anflu(R) with GSK China and recently launched an extensive marketing campaign. Seasonal influenza vaccine sales to CDCs typically occur during third quarter, subject to seasonality as people get vaccinated from the end of the third quarter to the beginning of the fourth quarter.

Research and Development

In April 2007, Sinovac was granted approval by the China State Food and Drug Administration (SFDA) to enter into Phase II clinical trials for Panflu, the Company's pandemic influenza vaccine (H5N1). The SFDA approval covered Phase Ib and Phase II trials of the whole viron vaccine and Phase I and Phase II trials of the split vaccine.

In December 2007, Sinovac reported positive top-line results of completed Phase II clinical trial of its pandemic influenza (H5N1) whole viron inactivated vaccine. The randomized, double-blind trial of the vaccine was designed to assess the safety and immunogenicity of the vaccine. The study included 402 volunteers, between the ages of 18 and 60, who were each vaccinated with two doses of 5 ug, 10 ug or 15 ug. The preliminary results of the trials suggested that each of the three dosages may induce varying degrees of immune response. In February 2008, the report with results from the Phase II trial of the whole viron inactivated vaccine was submitted for review to the SFDA.

In 2007, Sinovac initiated a co-development project with National Institute for Viral Disease Control and Prevention, China CDC to develop a universal pandemic influenza vaccine to against pandemic flu caused by unknown flu viruses. It's in pre-clinical trial and we expect to file a clinical trial application in 2010.

Conference Call Details

The Company will hold a conference call on Monday, March 31, 2008 at 9:00 a.m. ET (9:00 p.m. Beijing time). The conference call dial-in numbers are 1- 877-407-4018 (USA) or 1-201-689-8471 (international).

A replay of the call will be available from 12:00 p.m. ET on March 31, 2008 until April 14, 2008 at midnight. To access the replay, please dial 1- 877-660-6853 (USA) or 1-201-612-7415 (international) and reference the account number 3055 and the access code 279686. A live audio webcast of the call will also be available on the Investors section on the corporate web site at http://www.sinovac.com. A webcast replay can be accessed on the corporate website beginning March 31, 2008 and the replay will remain available for 30 days.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B) and Anflu(R) (influenza). Sinovac is currently developing human vaccines against the H5N1 strain of pandemic influenza, Japanese encephalitis and SARS. Additional information about Sinovac is available on its website, http://www.sinovac.com. To be added to our distribution list, please email: info@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Consolidated Statement of Operations and Comprehensive Income (Loss)

Three Months and Twelve Months Ended December 31, 2007 and 2006

(Expressed in U.S. Dollars)

Three months Twelve months

ended December 31 ended December 31

2007 2006 2007 2006

Sales 9,201,946 6,187,773 33,541,187 15,354,608

Cost of sales 2,915,135 1,308,609 6,502,328 4,231,785

Gross profit 6,286,811 4,879,164 27,038,859 11,122,823

Selling, general

and administrative

expenses 2,472,518 3,976,111 11,958,498 9,752,783

Research and

development

expenses 353,790 162,012 965,000 324,970

Depreciation and

amortization 165,750 152,656 640,568 605,262

Total operating

expenses 2,992,058 4,290,779 13,564,066 10,683,015

Operating income

(loss) 3,294,753 588,385 13,474,793 439,808

Interest and

financing

expenses (294,412) (95,129) (478,436) (319,197)

Interest and other

income 0 41,461 190,668 285,148

Income (loss)

before income

taxes and

minority

interest 3,000,341 534,717 13,187,025 405,759

Income taxes

recovery (expense) (42,478) 204,856 (1,974,118) (100,513)

Income (loss)

before minority

interest 2,957,863 739,573 11,212,907 305,246

Minority interest

share of (income)

loss (964,588) (558,934) (3,562,501) (1,001,279)

Net Income (loss)

for the year 1,993,275 180,639 7,650,406 (696,033)

Foreign currency

translation

adjustment 513,502 12,858 1,310,985 302,490

Comprehensive

income (loss) 2,506,777 193,497 8,961,391 (393,543)

Earnings (Loss) per

share

- Basic 0.05 0.005 0.19 (0.02)

- Diluted 0.05 0.004 0.19 (0.02)

Weighted average

number of shares

of common stock

outstanding

- Basic 40,312,158 39,893,803 40,254,192 38,229,944

- Diluted 40,851,072 40,335,656 40,637,876 38,229,944

For more information, please contact:

Helen G. Yang

Sinovac Biotech Ltd.

Phone: +86-10-82890088 x871

Fax: +86-10-62966910

Email: info@sinovac.com

Investors/Media:

Stephanie Carrington/Janine McCargo

The Ruth Group

Tel: +1-646-536-7017 /7033

Email: scarrington@theruthgroup.com / jmccargo@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Announces Postponement of Annual General Meeting
2. Sinovac Requests Extension for Annual Shareholders Meeting
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Sinovac Closes $9.75 Million Private Placement
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Sinovac Announces Adjournment of Annual General Meeting
7. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Cenna Bioscience ... for the treatment of Alzheimer’s disease, announced today it has been selected to present ... at the Breakers in Palm Beach, Florida. The purpose of the Forum is ...
(Date:2/9/2016)... Cupertino, CA (PRWEB) , ... February 08, 2016 ... ... and multilingual testing services, announced today the launch of its revamped and ... range of scalable language service solutions, the redesigned website will better communicate how ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... for Public Policy for the National Organization for Rare Disorders (NORD). Dorman will ... ensure their voices are heard throughout the drug regulatory review process. , “Adding ...
(Date:2/9/2016)... BOSTON , Feb. 9, 2016 ... a data-driven, biological research approach, has announced the ... Financial Officer and Chief Operating Officer. Haddock brings ... corporate finance, including 12 years in senior financial ... global experience in business organizational management. ...
Breaking Biology Technology:
(Date:2/3/2016)... Calif. , Feb. 3, 2016 Vigilant ... Police Department in Missouri ... license plate reader (LPR) data from Vigilant Solutions. ... hit-and-run case in which the victim was walking out of a convenience ... parking space next to his vehicle, striking his vehicle ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
(Date:2/1/2016)... 1, 2016 Rising sales of ... global touchfree intuitive gesture control market size ... sales of consumer electronics coupled with new technological advancements ... size through 2020   --> ... new technological advancements to drive global touchfree intuitive gesture ...
Breaking Biology News(10 mins):